

RECEIVED  
APR 07 2003 1636

TECH CENTER 10/19/01 (08-00)

Approved for use through 10/31/2002/OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/015,551	
	Filing Date	December 11, 2001	
	First Named Inventor	Keith D. ALLEN	
	Group Art Unit	1636	
	Examiner Name	Quang NGUYEN	
Total Number of Pages in This Submission	5	Attorney Docket Number	R-227

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply - Restriction <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Kelly L. Quast, Reg. No. 52,141
Signature	
Date	March 27, 2003


CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 3/27/03			
Typed or printed name	Deborah A. Mojarro		
Signature		Date	March 27, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

BEST AVAILABLE COPY



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**



Applicant: **Keith D. ALLEN**

Serial No.: **10/015,551**

Filed: **December 11, 2001**

Title: **Transgenic Mice Containing Brain-Specific Membrane-Anchored Protein Gene Disruptions**

Group Art Unit: **1636**

**47**

Examiner: **Nguyen, Quang**

Customer No. **26619**

Docket/Order No. **R-227**

Date: **March 27, 2003**

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed February 26, 2003, concerning the Examiner's restriction to the claims, Applicant hereby provisionally elects, with traverse, Invention II (claims 1-12, 15, 17-26 and 30), drawn to a targeting construct for a brain-specific membrane-anchored protein (BSMAP), a method of producing the targeting construct, a non-human transgenic animal or mouse comprising a disruption in a BSMAP gene, an isolated cell derived from the same transgenic animal or mouse, methods of producing the same transgenic mouse, and methods for identifying an agent that modulates the expression or the function of a BSMAP gene using the same transgenic animal or mouse or cells derived from the same.

In the restriction, the Examiner asserts that claims 1-32 are drawn to five distinct subjects, grouped as: Invention Group I (claims 1-7, 13-14 and 27-28), drawn to a targeting construct for a brain-specific membrane-anchored protein (BSMAP), method of producing the targeting construct, and isolated cell comprising a disruption in a BSMAP gene and methods of identifying an agent that modulates the expression or the function of a BSMAP gene using the same cell; Invention Group II (claims 1-12, 15, 17-26 and 30), drawn to a targeting construct for a brain-specific membrane-anchored protein (BSMAP), a method of producing the targeting construct, a non-human transgenic animal or mouse comprising a disruption in a BSMAP gene, an isolated cell derived from the same transgenic animal or mouse, methods of producing the same transgenic mouse, and methods for identifying an agent that modulates the expression or the function of a BSMAP gene using the same

**BEST AVAILABLE COPY**

transgenic animal or mouse or cells derived from the same; Invention Group III (claims 16 and 29), drawn to an agent identified by the methods of the presently claimed invention; Invention Group IV (claim 31), drawn to an agonist or antagonist of a BSMAP; and Invention Group V (claim 32), drawn to phenotypic data associated with the transgenic mouse of the presently claimed invention wherein the data is in a database. Applicant respectfully traverses the requirement for restriction and requests reconsideration and withdrawal of the requirement.

As stated in MPEP §803, the requirements for a proper claim restriction are as follows: “(a) the inventions must be independent or distinct as claimed; and (b) there must be a serious burden on the examiner if restriction is required.”

A proper claim restriction must place a “serious burden” on the Examiner if the claims were examined without a restriction. In order to establish a serious burden, the Examiner must “show by appropriate explanation one of the following: separate classification thereof, a separate status in the art, or a different field of search.” This showing of a serious burden is required even if the claimed inventions have been shown to be distinct. See MPEP §808.02

The instant Office Action generally asserts that restriction is warranted between Invention Groups I through V in that the claimed inventions are chemically, physically and structurally distinct. The Examiner has further based the restriction of claims on, for example, alleged differences in starting materials, method steps and technical considerations of claimed methods. However, the Applicant submits that the Examiner has not established that a serious burden would result from a search of the invention groups together. The Applicant does not believe that the Examiner has fulfilled the requirements for a proper claim restriction based on a serious burden standard.

Specifically, the Examiner asserts that the cell comprising a disruption in a BSMAP gene of Group I, the non-human transgenic animal or mouse comprising a disruption in a BSMAP gene of Group II, the agent identified of Group III, the agonist and antagonist of a BSMAP of Group IV and the phenotypic data in a database of Group V are chemically, physically and structurally distinct one from the others. The Examiner further concludes that the cell of Group I can be made by means other than the transgenic non-human animal or mouse of Group II. The Examiner also asserts that the methods in Group I differ from those of Group II because they involve different starting materials, different method steps and different technical considerations for attaining different desired results. The Applicant respectfully disagrees with the Examiner’s conclusions. The Applicant submits that the subject matter of each of these Invention Groups is related. A reasonable

search of the prior art on an aspect of the subject matter of the claims of any one of the Invention Groups, *e.g.* disruptions in a brain-specific membrane-anchored protein gene in a mouse, would reveal results that would encompass the subject matter of each group. Thus, a serious burden to the Examiner would not result as a separate search or examination would not be required.

Although the Applicant has provisionally elected Invention II for the purposes of advancing prosecution of the present application, the Applicant contends for the foregoing reasons that the requirement for restriction between Inventions I through V is improper. Accordingly, the Applicant respectfully requests reconsideration and withdrawal of the requirement.

Respectfully submitted,

Date: 3/27/03


Kelly L. Quast  
Kelly L. Quast (Reg. No. 52,141)

Deltagen, Inc.  
740 Bay Road  
Redwood City, CA 94063  
(650) 569-5100

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8**

I hereby certify that this correspondence and its listed enclosures is being deposited with the United States Postal Service as First Class Mail, postage paid, in an envelope addressed to:  
Commissioner for Patents, Washington, D.C. 20231 on **March 27, 2003**

Name: **Deborah A. Mojarro**

Signed: 

Date: 3/27/03